Acuta Capital Partners, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Acuta Capital Partners, LLC reported 38 stock positions worth $99.4 million. Its top holding was Ocular Therapeutix (OCUL) at 9.5% of the portfolio, followed by Insmed (INSM, 7.3%) and Tourmaline Bio (TRML, 7.2%). Compared with Q3 2024, it opened 8 new positions, sold out of 10, added to 12 and reduced 15. The biggest buy was Praxis Precision Medicines I (PRAX, shares +17%) and the biggest sale Vaxcyte (PCVX, shares −67%).
- Most Recent 13F
- Q2 2026
- Location
- REDWOOD CITY, CA
- CIK
- 0001582844
- Portfolio Value
- $99.4M (Q4 2024)
- SEC Filing
- 0001104659-25-013432 ↗ filed Feb 14, 2025
Holdings Value
Holdings 38 stocks · $99.4M
| OCUL Ocular Therapeutix Inc. | 9.55% | 1,111,071 | $9.5M | Reduce -6.6% |
| INSM Insmed Inc. | 7.28% | 104,800 | $7.2M | Reduce -2.5% |
| TRML Tourmaline Bio Inc. | 7.18% | 351,842 | $7.1M | Add +6.0% |
| CRNX Crinetics Pharmaceuticals Inc. | 6.32% | 122,900 | $6.3M | Reduce -6.7% |
| ELVN Enliven Therapeutics Inc. | 6.05% | 267,368 | $6.0M | Reduce -9.8% |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 5.87% | 1,849,402 | $5.8M | No change |
| PRAX Praxis Precision Medicines I | 5.23% | 67,500 | $5.2M | Add +17.4% |
| RVMD Revolution Medicines Inc. | 4.92% | 111,700 | $4.9M | Add +3.4% |
| ARGX Argenx SE - ADR | 4.28% | 6,910 | $4.2M | Add +17.1% |
| PCVX Vaxcyte Inc. | 3.71% | 45,000 | $3.7M | Reduce -66.8% |
| TRVI Trevi Therapeutics Inc. | 3.20% | 771,958 | $3.2M | Add +165.7% |
| ASND Ascendis Pharma A/S | 3.18% | 22,976 | $3.2M | Add +9.4% |
| MREO Mereo Biopharma Group PL-ADR | 2.74% | 779,308 | $2.7M | Reduce -38.2% |
| DRUG Bright Minds Biosciences Inc. | 2.51% | 69,124 | $2.5M | New |
| TERN Terns Pharmaceuticals Inc. | 2.49% | 447,500 | $2.5M | Reduce -8.1% |
| EWTX Edgewise Therapeutics Inc. | 2.35% | 87,658 | $2.3M | Add +39.1% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.91% | 180,945 | $1.9M | No change |
| UNICYCIVE THERAPEUTICS INC | 1.84% | 2,303,000 | $1.8M | Add +16.4% |
| RCKT Rocket Pharmaceuticals Inc. | 1.70% | 134,500 | $1.7M | Reduce -29.2% |
| LQDA Liquidia Corp. | 1.63% | 137,709 | $1.6M | Add +87.4% |
| MERSANA THERAPEUTICS INC | 1.61% | 1,120,500 | $1.6M | Reduce -6.6% |
| TSHA Taysha Gene Therapies Inc. | 1.54% | 884,244 | $1.5M | Reduce -58.3% |
| TECX Tectonic Therapeutic Inc. | 1.53% | 33,008 | $1.5M | Add +140.9% |
| CDTX Cidara Therapeutics Inc. | 1.47% | 54,473 | $1.5M | New |
| NAMS Newamsterdam Pharma Co. NV | 1.29% | 50,000 | $1.3M | New |
| ZYME Zymeworks Inc. | 0.99% | 67,240 | $984K | New |
| ELDN Eledon Pharmaceuticals Inc. | 0.98% | 235,750 | $971K | New |
| VERV Verve Therapeutics Inc. | 0.91% | 160,200 | $904K | Add +9.7% |
| RARE Ultragenyx Pharmaceutical Inc. | 0.89% | 21,000 | $883K | Reduce -16.3% |
| GILD Gilead Sciences Inc. | 0.85% | 9,150 | $845K | Reduce -53.1% |
| ACLX Arcellx Inc. | 0.83% | 10,743 | $824K | Reduce -82.7% |
| SGMOQ Sangamo Therapeutics Inc. | 0.76% | 740,000 | $755K | New |
| THRD Third Harmonic Bio Inc. | 0.52% | 49,800 | $512K | Add +221.1% |
| ARTV Artiva Biotherapeutics Inc. | 0.45% | 44,000 | $444K | No change |
| FBRX Forte Biosciences Inc. | 0.41% | 18,139 | $412K | New |
| CRVS Corvus Pharmaceuticals Inc. | 0.40% | 74,307 | $398K | New |
| CELC Celcuity Inc. | 0.33% | 25,000 | $327K | Reduce -46.4% |
| RAPP Rapport Therapeutics Inc. | 0.29% | 16,400 | $291K | Reduce -6.8% |
Other holdings (1): bonds, preferreds, convertibles and warrants · $21K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 90,832 | $21K | No change |
Total filed on the 13F, all lines: $99.4M.
Portfolio Sells Q3 2024 → Q4 2024
| PCVX Vaxcyte Inc. | Reduce -66.8% | 3.71% | −8.83 |
| ACLX Arcellx Inc. | Reduce -82.7% | 0.83% | −3.37 |
| KURA Kura Oncology Inc. | Sold out | 0.00% | −3.12 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −1.97 |
| TSHA Taysha Gene Therapies Inc. | Reduce -58.3% | 1.54% | −1.91 |
| SLRN Acelyrin Inc. | Sold out | 0.00% | −1.45 |
| MREO Mereo Biopharma Group PL-ADR | Reduce -38.2% | 2.74% | −1.45 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −1.34 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -29.2% | 1.70% | −1.14 |
| TERN Terns Pharmaceuticals Inc. | Reduce -8.1% | 2.49% | −0.80 |
| GERN Geron Corp. | Sold out | 0.00% | −0.57 |
| GILD Gilead Sciences Inc. | Reduce -53.1% | 0.85% | −0.47 |
| CRBP Corbus Pharmaceuticals Holdi | Sold out | 0.00% | −0.31 |
| CYPH Cypherpunk Technologies Inc. | Sold out | 0.00% | −0.25 |
| RARE Ultragenyx Pharmaceutical Inc. | Reduce -16.3% | 0.89% | −0.24 |
| CELC Celcuity Inc. | Reduce -46.4% | 0.33% | −0.23 |
| MERSANA THERAPEUTICS INC | Reduce -6.6% | 1.61% | −0.22 |
| CLYM Climb Bio Inc. | Sold out | 0.00% | −0.22 |
| BNTC Benitec Biopharma Inc. | Sold out | 0.00% | −0.22 |
| TVTX Travere Therapeutics Inc. | Sold out | 0.00% | −0.22 |
| ELVN Enliven Therapeutics Inc. | Reduce -9.8% | 6.05% | −0.08 |
| RAPP Rapport Therapeutics Inc. | Reduce -6.8% | 0.29% | +0.00 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -6.7% | 6.32% | +0.87 |
| INSM Insmed Inc. | Reduce -2.5% | 7.28% | +0.92 |
| OCUL Ocular Therapeutix Inc. | Reduce -6.6% | 9.55% | +1.16 |
Portfolio Buys Q3 2024 → Q4 2024
| PRAX Praxis Precision Medicines I | Add +17.4% | 5.23% | +2.55 |
| DRUG Bright Minds Biosciences Inc. | New | 2.51% | +2.51 |
| TRVI Trevi Therapeutics Inc. | Add +165.7% | 3.20% | +2.41 |
| ARGX Argenx SE - ADR | Add +17.1% | 4.28% | +1.69 |
| CDTX Cidara Therapeutics Inc. | New | 1.47% | +1.47 |
| NAMS Newamsterdam Pharma Co. NV | New | 1.29% | +1.29 |
| TECX Tectonic Therapeutic Inc. | Add +140.9% | 1.53% | +1.20 |
| UNICYCIVE THERAPEUTICS INC | Add +16.4% | 1.84% | +1.19 |
| LQDA Liquidia Corp. | Add +87.4% | 1.63% | +1.03 |
| EWTX Edgewise Therapeutics Inc. | Add +39.1% | 2.35% | +0.99 |
| ZYME Zymeworks Inc. | New | 0.99% | +0.99 |
| ELDN Eledon Pharmaceuticals Inc. | New | 0.98% | +0.98 |
| RVMD Revolution Medicines Inc. | Add +3.4% | 4.92% | +0.95 |
| SGMOQ Sangamo Therapeutics Inc. | New | 0.76% | +0.76 |
| ASND Ascendis Pharma A/S | Add +9.4% | 3.18% | +0.64 |
| FBRX Forte Biosciences Inc. | New | 0.41% | +0.41 |
| CRVS Corvus Pharmaceuticals Inc. | New | 0.40% | +0.40 |
| THRD Third Harmonic Bio Inc. | Add +221.1% | 0.52% | +0.35 |
| VERV Verve Therapeutics Inc. | Add +9.7% | 0.91% | +0.34 |
| TRML Tourmaline Bio Inc. | Add +6.0% | 7.18% | +0.26 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $143.5M | PRAX, WHWK, TNGX, STRO, AVBP |
| Q1 2026 | 26 | $140.6M | PRAX, TERN, WHWK, TNGX, DRUG |
| Q4 2025 | 29 | $147.3M | TERN, PRAX, CDTX, OCUL, WHWK |
| Q3 2025 | 27 | $96.8M | OCUL, CDTX, TRML, WHWK, INSM |
| Q2 2025 | 27 | $71.6M | OCUL, CDTX, WHWK, SLNO, TRML |
| Q1 2025 | 33 | $86.2M | OCUL, INSM, TRML, WHWK, ELVN |
| Q4 2024 | 38 | $99.4M | OCUL, INSM, TRML, CRNX, ELVN |
| Q3 2024 | 40 | $123.5M | PCVX, OCUL, TRML, INSM, ELVN |
| Q2 2024 | 31 | $118.6M | OCUL, ELVN, PCVX, DYN, PRAX |
| Q1 2024 | 32 | $153.9M | OCUL, PRAX, MERSANA THERAPEUTICS INC, TSHA, RCKT |